Drug Profile
Research programme: radiopharmaceuticals and imaging agents - Principio
Alternative Names: Curinal; Curinal (EBV tumour radiotherapy) - Principio; Prostara; Prostara (prostate radiotherapy) - Principio; Prostavis (prostate imaging agent) - Principio; Visinal (EBV tumour imaging agent) - PrincipioLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Principio
- Class Imaging agents; Radiopharmaceuticals
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Prostate-cancer in USA
- 16 Jul 2016 No recent reports of development identified for research development in Prostate-cancer(Diagnosis) in USA
- 16 Jul 2016 No recent reports of development identified for research development in Solid-tumours in USA